AdvanCell
PrivateLast Round
Series D
Jul 15, 2026
Total Funding Raised
$472.97M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
AdvanCell is a clinical-stage radiopharmaceutical company that develops targeted alpha therapies for cancer treatment using a proprietary Lead-212 platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AdvanCell Comparables
Compare AdvanCell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ARTBIO | 89% | |
| Alpha-9 Oncology | 87% | |
| Convergent Therapeutics | 85% |
For institutional investors. Book with your work email.
AdvanCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 15, 2026 | ||||
| Grant | May 9, 2026 | ||||
| Grant | Apr 14, 2025 | ||||
| Series C | Feb 3, 2025 | ||||
| Grant | Jul 5, 2023 | ||||
Series B | Aug 23, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AdvanCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series D |
| SymBiosis Capital Management | Series D, Series C |
| SV Health Investors | Series D, Series C |
| Time BioVentures | Series D |
| Ally Bridge Group | Series D |
| Eventide Funds | Series D |
| Morningside Ventures | Series D, Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2026
Open roles increased to 20, 2.1x the trailing average.
- Sep 14, 2026
Open roles increased to 16, 2.4x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 4, 2026
AdvanCell Pty Ltd. appoints Andy Porter as Chief People Officer on Nov 4th '26 to oversee global people and information technology functions as it advances late-stage clinical development and international expansion.
- invests_into_assetsOct 2, 2026
AdvanCell Pty Ltd. leased the 128,000-square-foot 1 Corporate Drive building in Massachusetts in June '26
- expands_offices_toSep 17, 2026
AdvanCell Pty Ltd. expands its presence to Massachusetts by signing a 128,000-square-foot life sciences lease and occupying the entire building at 1 Corporate Drive within Innovation Park on Sep 17th '26.
- hiresSep 15, 2026
AdvanCell Pty Ltd. appoints Sean Cassidy as Chief Financial Officer on Sep 15th '26 as it advances its radiopharmaceutical pipeline.
For institutional investors. Book with your work email.
AdvanCell Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AdvanCell's valuation, stock price, and market status.
Is AdvanCell a public or private company?
AdvanCell is a private company.
What is the current stock price of AdvanCell?
AdvanCell is a private company, so its shares have no public market price. Caplight tracks AdvanCell's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AdvanCell worth (valuation)?
Valuation information for AdvanCell is not publicly available.
Can I buy AdvanCell stock?
AdvanCell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AdvanCell's last funding round?
AdvanCell's most recent funding round was Series D on July 15, 2026.
Who are the main investors in AdvanCell?
Key investors in AdvanCell include SymBiosis Capital Management, SV Health Investors, Ally Bridge Group, Morningside Ventures, Abingworth.
Will AdvanCell IPO soon?
No public IPO plans have been announced for AdvanCell.
How can I track AdvanCell secondary market activity?
Caplight tracks bids, offers, and trades in AdvanCell's shares on secondary markets.